Dynavax Technologies Corporation(NASDAQ:DVAX) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during After-hours on Aug 5, 2016. Company reported revenue of $2.65M. Analysts estimated a revenue of $1.24M. Earnings per share were $-0.75. Analysts had estimated an EPS of $-0.72.
Dynavax Technologies Corporation (DVAX) shares turned negative on Wednesdays trading session with the shares closing down -0.31 points or -1.94% at a volume of 8,04,029. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $16.09. The peak price level was also seen at $16.09 while the days lowest was $15.54. Finally the shares closed at $15.63. The 52-week high of the shares is $32.49 while the 52-week low is $12.84. According to the latest information available, the market cap of the company is $602 M.
Several Insider Transactions has been reported to the SEC. On Jun 30, 2016, Robert Janssen (Vice President) purchased 1,452 shares at $13.68 per share price.Also, On May 23, 2016, Eddie Gray (CEO) purchased 2,750 shares at $15.57 per share price.
Dynavax Technologies Corporation (Dynavax) is a clinical-stage biopharmaceutical company. The Company uses toll-like receptor (TLR) biology to discover and develop vaccines and therapeutics. Its development programs are organized under three areas of focus: vaccine adjuvants cancer immunotherapy and autoimmune and inflammatory diseases. The Companys pipeline of product candidates includes HEPLISAV-B an investigational adult hepatitis B vaccine is in Phase III clinical trials; SD-101 a cancer immunotherapy candidate is in Phase I/II clinical trials; AZD1419 a candidate drug for asthma is in Phase II clinical trials planning; DV1179 is an inhibitor of TLR 7 and TLR 9 for autoimmune and inflammatory diseases is in Phase I clinical trials. DV230-Nanoparticle is a second generation adjuvant. DV230-Nanoparticle is in preclinical stage.